ANI Pharmaceuticals (NASDAQ: ANIP) net income
ANI Pharmaceuticals reported a net profit of $78.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $18.5m. Its net margin was 8.9%. Earnings per share were $3.50.
Fiscal 2025 is the highest of the 10 fiscal years on record for ANI Pharmaceuticals. The biggest drop was in fiscal 2019, −60.7%. It reported a loss in 5 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $78.3m | — | 8.9% | $3.50 |
| 2024 | −$18.5m | −198.6% | −3.0% | −$1.04 |
| 2023 | $18.8m | — | 3.9% | $0.86 |
| 2022 | −$47.9m | — | −15.1% | −$3.05 |
| 2021 | −$42.6m | — | −19.7% | −$3.40 |
| 2020 | −$22.5m | −470.0% | −10.8% | −$1.88 |
| 2019 | $6.1m | −60.7% | 3.0% | $0.51 |
| 2018 | $15.5m | — | 7.7% | $1.31 |
| 2017 | −$1.1m | −127.4% | −0.6% | −$0.09 |
| 2016 | $3.9m | — | 3.1% | $0.34 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ANI Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, ANI Pharmaceuticals ranks 119th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of ANI Pharmaceuticals, 8.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 117th | Keros Therapeutics | $87.0m | 35.7% |
| 118th | Zevra Therapeutics | $83.2m | 78.2% |
| 119th | ANI Pharmaceuticals | $78.3m | 8.9% |
| 120th | Sotera Health | $77.9m | 6.7% |
| 121st | Amneal Pharmaceuticals | $72.1m | 2.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of ANI Pharmaceuticals
- How much did ANI Pharmaceuticals earn in fiscal 2025?
- ANI Pharmaceuticals reported a net profit of $78.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $18.5m.
- What are the earnings per share of ANI Pharmaceuticals?
- They were $3.50 in fiscal 2025, compared with −$1.04 in fiscal 2024.
- What is the net margin of ANI Pharmaceuticals?
- In fiscal 2025 its net profit was 8.9% of its revenue.
- What was the most profitable year for ANI Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $78.3m.
- Where does ANI Pharmaceuticals rank in its sector by net income?
- It ranks 119th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for ANI Pharmaceuticals come from?
- From the annual report (Form 10-K) that ANI Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ANI Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on ANI Pharmaceuticals: the ANI Pharmaceuticals page · annual accounts · revenue · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.